Published in Cancer Detection and Prevention 2000; 24(Supplement 1).

Estimation of glycogen levels in human colorectal cancer tissue: relationship with cell cycle and tumor outgrowth

A Satomi, S Takahashi, K Yano, H Kawase, T Tanimizu, H Takahashi, M Sakai, A Hinoki, R Hirayama

Dept1 Pediatric Surgery,, 2 Chemistry Saitama Medical School, Irumagun, Saitama, Japan

AIM: We quantitatively measured glycogen levels in tissue samples obtained from tumors, regions adjacent to tumor, and regions of normal colorectum to determine whether the levels were related to cell cycle and cancer growth. METHODS: Glycogen levels were analyzed in relation to histopathological factors, and cell cycle progression. RESULTS: The glycogen level was found to be highest in the cancer tissue, lower in normal tissue, and lowest in the adjacent tissue. The difference in glycogen level between the cancer tissue and the other two regions was significant. There was a negative correlation between glycogen level and tumor size, but it was not significant. The level of glycogen in cancer tissues decreased as the stage of the disease progressed, but a significant difference was not found between stages. There was negative correlation between the glycogen level and the proliferation index. There was a positive correlation between the glycogen level and the proportion of cancer cells in G1 phase, while there was a negative correlation with S and G2M phases. Glycogen levels were highest in cancers with a high proportion of cells in G1, and decreased with progressions to S phase. CONCLUSIONS: It may be that glycogen is utilized in the progression to S phase, and cancer tissues are supplied with glycogen from the tumors themselves as well as their adjacent tissues. Cancer growth may be inhibited by artificial control of the glycogen level in the G1 phase of cancer cells.

KEY WORDS: Fourier transform-infrared spectroscopy, Glycogen, Colorectal cancer, Cell cycle.

For more information, contact

Paper presented at the International Symposium on Impact of Biotechnology on Cancer Diagnostic & Prognostic Indicators; Geneva, Switzerland; October 28 - 31, 2000; in the section on cell cycle inhibitors.